Skip to main content

News Releases

IDEAYA Biosciences, Inc. appoints Bao Truong as Vice President, Head of Regulatory Affairs

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery and development of breakthrough precision medicines, announced today the appointment of Bao Truong, as vice president, head of regulatory affairs. 

"We are pleased to welcome Bao to IDEAYA," said Yujiro S. Hata, chief executive officer of IDEAYA. "Bao is an experienced regulatory professional with a proven ability to work with the FDA and other regulatory authorities to obtain drug approvals."  Julie Hambleton, IDEAYA chief medical officer, added, "Bao's experience will help us develop IDE196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and GNA11 mutations, including metastatic uveal melanoma (MUM), as well as our other pipeline assets."  

Bao is a biotech professional with over thirteen years of regulatory experience in oncology product development.  Bao has led teams and executed with responsibility for regulatory processes and oversight of product development, including pre-clinical, clinical and post-market approval, as well as of CMC, regulatory operations publishing, companion diagnostics and quality assurance.  Bao served most recently as vice president, head of regulatory affairs at Ignyta, where she helped drive entrectinib's clinical development plan (from Phase 1/Expansion to registration-enabling single-arm global Phase 2 basket trial) with potential to support both tissue specific and tissue agnostic indications. 

Prior to Ignyta, Bao served as head of regulatory affairs at Aragon Pharmaceuticals and Seragon Pharmaceuticals, effecting the clinical regulatory plan for the first FDA-approved therapy of a drug in non-metastatic castrate resistant prostate cancer using a novel clinical trial endpoint while at Aragon.  Bao previously served as global regulatory lead at Genentech for Erivedge, the first FDA- approved therapeutic for advanced, basal cell carcinoma, and held positions of increasing responsibility for multiple oncology products, including Kadcyla, Gazyva, Tarceva and Herceptin. 

Earlier in her career, Bao worked in oncology research at University of California, San Diego and University of California, San Francisco.  Bao earned her B.S., Biochemistry, from University of California, San Diego.


IDEAYA is a precision medicine oncology company developing targeted therapeutics and translational biomarkers to guide patient treatment.  IDEAYA's pipeline is directed to tumor cell and immune oncology targets approached using synthetic lethality and direct targeting of oncogenic pathways.  Headquartered in South San Francisco, California, IDEAYA has assembled leading scientists, professionals  and advisors with extensive knowledge and expertise in cancer biology, immunology, small molecule chemistry, biomarker discovery, and clinical development.

Investor and Media Contact:
IDEAYA Biosciences
Paul Stone
SVP, General Counsel and Head of Operations

Close Menu